Executive Director, Emerging Therapeutic Areas

GSK•Philadelphia, PA

4d•Hybrid

About The Position

The Executive Director, Emerging Therapeutic Areas provides strategic US medical leadership for key pipeline oncology assets, delivering an integrated US voice into research and development plans to increase relevance and impact of pipeline assets for the US market. Through cross-functional partnership, the role advocates for development and evidence strategies that align with future US treatment landscape and stakeholder expectations, helping to optimize clinical relevance and operational feasibility of oncology clinical trial programs. The role leads the US Medical Oncology Emerging Therapeutic Areas team, integrating headquarters medical strategy with field medical execution to ensure robust bidirectional insight generation, support clinical trial site selection and enrollment, and build medical and evidence foundations required for successful transition of assets for commercialization. This role works with the US Oncology Therapeutic Head to ensure the US Medical Oncology Emerging Therapeutic Areas team has the appropriate expertise and resources in place to support new medicines coming to market. They will partner closely with Commercial Early Asset leads, Market Access, Global Medical Affairs, and R&D teams.

Requirements

PhD, PharmD, MD, or equivalent advanced health professional degree.
5 + years in Oncology Medical Affairs pharmaceutical industry roles, with at least 3 years in US-focused roles.
Experience influencing clinical development strategy and protocol design for pipeline assets through medical insight and cross-functional collaboration.

Nice To Haves

Strong oncology expertise, with experience across multiple therapeutic areas such as lung, GU, GI, and GIST
Experience leading US medical strategy for pipeline or early asset programs
Experience leading or partnering with field medical organizations and leveraging field-generated insights to inform strategy
Strong understanding of US oncology practice patterns, treatment landscapes, and healthcare system dynamics
Experience in evidence planning, integrated evidence strategy, or collaboration with HEOR and Value & Access teams
Demonstrated ability to lead cross-functional initiatives in a complex, matrixed environment
Proven ability to build and sustain relationships with external oncology experts and investigators
Strong leadership, communication, and strategic thinking skills, with experience managing medical teams

Responsibilities

Direct and oversee the US Medical Oncology Emerging Therapeutic Areas team, establishing priorities, ensuring alignment, and driving high-quality scientific and strategic execution.
Drive Medical Affairs activities to understand US unmet needs, healthcare delivery patterns, access dynamics, and customer stakeholders in key tumor areas
In partnership with Commercial and Market Access, develop integrated US point of view on unmet needs and commercial challenges and opportunities in priority tumor areas, including resourcing needs and potential go to market plans for future launches.
Shape Clinical trial protocol design, eligibility criteria, endpoints, comparator strategy, and study feasibility to increase US relevance and operational viability.
Lead development and oversee execution of US Medical Plans for priority oncology pipeline assets, ensuring team activities align with asset strategy; Co-create (with Global Medical Affairs) integrated evidence generation plans, ensuring evidence strategies address future treatment decision-making and value demonstration needs.
Set strategic direction for Lung/GU/GI MSL engagement, ensuring the team generates meaningful insights, sustains strong external expert relationships, and identifies investigators and research-ready sites aligned with pipeline priorities.
Develop and maintain a robust US external expert map, guiding team efforts to engage academic and community leaders, cooperative groups, and research networks to support pipeline strategy and scientific exchange.
Establish medical and scientific foundations for future asset transitions, ensuring early scientific communication approaches, disease education considerations, and stakeholder engagement strategies are appropriately shaped.